USPTO Patent Application: Nucleoside Derivative for Inflammation Treatment
Summary
The USPTO has published a patent application (US20260083743A1) detailing a nucleoside derivative for preventing and treating inflammation. The application, filed by WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY, claims the derivative offers better efficacy and fewer side effects than existing treatments like indometacin.
What changed
The United States Patent and Trademark Office (USPTO) has published patent application US20260083743A1, filed by WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY. The application describes a novel nucleoside derivative intended for the prevention and treatment of inflammatory diseases, including pancreatitis, hepatitis, and arthritis. It asserts that this derivative demonstrates superior efficacy and a significantly better side effect profile compared to established anti-inflammatory drugs such as indometacin, aspirin, ibuprofen, and glucocorticoids.
This publication represents a new patent application and does not impose immediate regulatory obligations on pharmaceutical companies or drug manufacturers. However, it signifies potential future intellectual property rights and market exclusivity for the assignee. Companies involved in the development of anti-inflammatory drugs should be aware of this filing as it may impact their research and development strategies and competitive landscape in the pharmaceutical sector.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF
Application US20260083743A1 Kind: A1 Mar 26, 2026
Assignee
WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY
Inventors
Wen Huang
Abstract
The present invention provides a nucleoside derivative for preventing and treating inflammation and an application thereof in the preparation of a drug for preventing and treating inflammatory diseases. The nucleoside derivative for preventing and treating inflammation provided by the present invention can significantly ameliorate conditions of pancreatitis, hepatitis, arthritis and the like, ameliorate organ injury and inflammatory indexes, and have better effects than positive control drug, indometacin. Compared with the conventional anti-inflammatory drugs, aspirin, ibuprofen, indomethacin, phenylbutazone, diclofenac, piroxicam and glucocorticoids, the nucleoside derivative for preventing and treating inflammation provided by the present invention has the advantage of significantly fewer side effects.
CPC Classifications
A61K 31/522 A61K 31/513 A61P 1/16
Filing Date
2025-12-02
Application No.
19406763
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.